Privately held stealth mode clinical stage oncology biopharmaceutical company that has completed multiple Phase I and II clinical trials in around 100 subjects with encouraging results. Significantly, the lead candidate has resulted in complete responses in both of the first two advanced stage cancer patients treated using an optimized clinical strategy. One patient was an advanced endometrial cancer patient and the other an advanced treatment-refractory triple negative breast cancer patient. Dr. Nelson identified a novel mechanism of action for the lead drug candidate and has spearheaded a new clinical trial in platinum-resistant ovarian cancer patients.

• Former Chairman of the Board• Former Vice Chairman of the Board• Former Co-Chair: Personalized Medicine Series• Executive Committee

• Negotiated effective sale of the company to one of the fastest growing private companies in the US• Responsible for P&L, negotiating partnerships and exit, and presentations at meetings and national investor conferences• Mission to improve health leveraging behavioral science and mobile technology• Many major corporate partnerships including Qualcomm, Sanofi Aventis, Johnson & Johnson, Janssen Pharmaceuticals, North Shore Health Systems• Many non-profit partnerships including NCI, NIH, UCLA, UCSD, U Penn, U of Minnesota and Susan G. Komen for the Cure• Multiple successful applications developed including weight loss, breast cancer prevention, medication adherence, rehab adherence, wellness tips, health coach facilitation, EMR SMS alerts, well baby reminders for low income mothers, and pharma clinical trial compliance• Apps successfully developed for multiple clinical trials• Commercial Apps launched on Google Play and the Apple iTunes App Store• Flexible APIs with Advanced Messaging Capabilities including international long-code support, personalization tags, timeouts, and message stacks• Personal messages based on reported behavior with continuous tailoring• Platform integration with devices including 2net (Qualcomm Life) and fitbit• Sent >1,000,000 messages to individuals to improve health

• EIR-like function to advise TSRI and create spin-out companies• Founded Epic Sciences in this role

• Founder and author of Executive Summary, Business Plan and Road Show• Raised Seed Financing, Convertible Debt, Series A and Series B totaling over $15MM• Series B included Domain Associates, Roche Ventures, Pfizer Ventures, and Angels• Architect for business, partnering, commercialization, and financing strategies• Sole negotiator for deals with 8 major pharmaceutical companies (Pfizer, Genentech, Celgene, Abbvie, BMS etc.) encompassing more than 60 individual projects with 5000 patients on over 20 clinical trials/studies • Pharma partnerships resulted in millions of dollars of non-dilutive revenue• Signed Partnership with Microsoft for Startup Acceleration Program and MS Azure Services• Architect of international strategy and sole negotiator for LabCorp partnership for European clinical trials• Directed cloud based data acquisition and cloud computing strategies for scalability and global harmonization• Presented at many scientific and investor conferences• First employee, grew the company to 30 employees• Identified and negotiated terms and conditions on multiple facilities during rapid expansion• Planned regulatory path and successfully passed audit from the NCI• Oversight for all finance and HR activities including securing a $5MM credit line from SVB• Directed filing, prosecution, and strategy of all Epic Intellectual Property including 12 patent applications and multiple trademarks• Initiated strategy to pursue independent products in addition to companion dx products• Directed development of protein and genomic content analysis on CTCs• Directed creation of a biorepository • Established collaborations with top-tier academic clinical researchers, especially in prostate cancer, including Drs. Howard Scher (MSKCC) and Johann De Bono (ICR London)• Principal Investigator on an SBIR Phase II grant ($1M), two SBIR Phase I grant ($350k), and QTDR grant ($244k) • Epic chosen as a 2013 “Cool Company” by the San Diego Venture Group

• Co-founded the company • Key negotiator to in-license Phase II drug candidate from a Japanese Pharmaceutical company• Negotiated license to partner for GI indications only while retaining other therapeutic indication

• Founded the company• Negotiated License to Phase II oncology assets from Merck

Clinical Gene Therapy BranchNational Human Genome Research Institute